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Abstract
The lymphatic system plays a critical role in melanoma metastasis, and yet, virtually no information exists regard-
ing the cellular and molecular mechanisms that take place between melanoma cells and the lymphatic vasculature.
Here, we generated B16-F1 melanoma cells that expressed high (B16α4+) and negligible (B16α4−) levels of α4 in-
tegrin to determine how the expression of α4 integrins affects tumor cell interactions with lymphatic endothelial cells
in vitro and how it impacts lymphatic metastasis in vivo. We found a direct correlation between α4 integrin expression
on B16-F1 melanoma cells and their ability to form adhesive interactions with monolayers of lymphatic endothelial
cells. Adhesion of B16-F1 melanoma cells to lymphatic endothelial cells was mediated by the melanoma cell α4 in-
tegrin binding to its counterreceptor, vascular cell adhesion molecule 1 (VCAM-1), that was constitutively expressed
on the lymphatic endothelial cells. VCAM-1 was also expressed on the tumor-associated lymphatic vessels of B16-F1
and B16α4+ tumors growing in the subcutaneous space of C57BL/6J mice. B16-F1 tumors metastasized to lymph
nodes in 30% of mice, whereas B16α4+ tumors generated lymph node metastases in 80% of mice. B16-F1 mela-
noma cells that were deficient in α4 integrins (B16α4−) were nontumorigenic. Collectively, these data show that the
α4 integrin expressed by melanoma cells contributes to tumorigenesis and may also facilitate metastasis to regional
lymph nodes by promoting stable adhesion of melanoma cells to the lymphatic vasculature.
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Introduction
Lymph nodes are the most common site of metastasis in patients
with melanoma, and assessment of the lymphatic compartment is a
critical component of the melanoma staging process [1,2]. Melanoma
that has spread to lymph nodes, but not to other tissues, is classified
as a stage III disease according to the American Joint Committee on
Cancer tumor/node/metastasis system [3]. Studies have shown that
one of the most powerful predictors of patient survival is the status
of regional lymph nodes [4]. More metastatic nodes correlate with de-
creased survival, and the 5-year survival for melanoma patients with
four or more positive nodes is approximately 25% [5]. Recent evi-
dence also suggests that some cutaneous melanomas may actually
stimulate the formation of new lymphatic vessels (i.e., lymphangio-
genesis) that encourage tumor cell metastasis to regional lymph nodes
[6]. However, despite the importance of the lymphatic circulation in
promoting the dissemination of melanoma, virtually no information
exists concerning the cellular and molecular interactions that take
place between melanoma cells and the lymphatic vasculature.
During recent years, much investigative effort has focused on the dra-
matic alterations that take place on the tumor cell surface during the
multistep progression of melanoma. For example, the expression of re-
ceptor complexes that participate in immune regulation becomes down-
regulated as the disease progresses [7,8], whereas there is a concomitant
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increase in the receptor density of proteins that regulate invasion and
metastasis [9,10]. One of the most extensively studied proteins that
mediate melanoma cell trafficking processes is the α4β1 integrin. Re-
ports examining the expression of α4β1 integrin in melanoma have
determined that the integrin is absent in primary and dysplastic nevi,
but that α4β1 expression increases during the transition from radial
growth phase to vertical growth phase [11,12]. Results generated
from clinical studies of melanoma demonstrated a direct correlation be-
tween α4β1 expression and occurrence of metastasis, reduced disease-
free survival, and decreased overall survival [12,13]. Several lines of
evidence suggest that melanoma cells may use their α4β1 integrin to
promote tumor cell retention in distal tissues. Examinations of the ad-
hesive interactions that take place between melanoma cells and blood
vascular endothelial cells indicate that tumor cell adhesion to activated
endothelial monolayers is mediated by the melanoma cell α4β1 integrin
binding to the inducible endothelial cell glycoprotein, vascular cell adhe-
sion molecule 1 (VCAM-1) [14,15]. In experimental models of mela-
noma metastasis, incubation of melanoma cells with antibodies directed
against α4β1 can significantly reduce the frequency of lung metastases in
mice that have been pretreated with proinflammatory cytokines [16].
During the course of melanoma progression in spontaneous melanoma
models, VCAM-1 becomes upregulated on the microvascular endo-
thelium of organs that are considered preferred sites of metastases [17].
Whereas the previously mentioned reports demonstrated that tu-
mor cell expression of α4β1 is critical for the hematogenous spread
of melanoma cells, the contribution of α4β1 to lymphatic metastasis
remains unknown. Recently, we generated a conditionally immortal-
ized lymphatic endothelial cell line from afferent vessels of the mouse
mesentery [18]. The lymphatic endothelial cell line enabled us to
identify redundant pathways that signal for lymphangiogenesis and
to define the molecular basis of therapy in a preclinical colon cancer
model [18]. In this report, we used the cell line to determine how the
expression of α4β1 integrin by B16-F1 melanoma cells affects their
ability to interact with lymphatic endothelial cells in vitro. To study
the effect of α4β1 on lymphatic metastasis in vivo, we established
B16-F1 melanoma cell lines expressing high (B16α4+) and negligible
(B16α4−) levels of α4 and implanted the cells into the subcutaneous
space of syngeneic C57BL/6J mice. Our findings suggest that the
ability of melanoma cells to form stable adhesive interactions with
lymphatic endothelial cells may be more important for lymphatic
metastasis than previously considered.
Materials and Methods
Reagents
The following antibodies were used in our study: anti-CD49d (integ-
rin α4) (553154), anti-CD29 (integrin β1) (553715), anti–vascular en-
dothelial growth factor receptor 3 (VEGFR-3) (552857), anti-CD16/
CD32 (553142), anti–VCAM-1 (550547) (BD PharMingen, San
Diego, CA); anti–VCAM-1 (sc-31048) and anti–CXCR-3 (sc-133121)
from Santa Cruz Biotechnology (Santa Cruz, CA); anti–CXCR-4
(54007; AnaSpec, Fremont, CA); anti–CC-chemokine receptor-7
(CCR-7, 2059-1; Epitomics, Inc, Burlingame, CA); anti–CCR-10
(GTX21661; GeneTex, Inc, Irvine, CA); anti-Prox1 (11-002; AngioBio,
Del Mar, CA); anti–β-actin (A5441; Sigma-Aldrich, St. Louis, MO);
anti–lymphatic vessel endothelial hyaluronic acid receptor 1 (LYVE-1,
10350PA50S; Fitzgerald Industries, Concord, MA); and anti–VCAM-1
(MCA2297; Serotec, Raleigh, NC). The following secondary antibodies
were used for colorimetric immunohistochemical analyses: goat anti-
rabbit Alexa 488 (A-11034) and goat antirat Alexa 594 (A-11007;
Molecular Probes, Inc, Eugene, OR).
For fluorescent-labeled cell sorting procedures, we used a goat antirat
immunoglobulin G (IgG) Fab2 fluorescein isothiocianate (FITC)–
conjugated secondary antibody (112-096-143; Jackson ImmunoResearch,
West Grove, PA). The following secondary antibodies were used for im-
munoblot analysis: peroxidase-conjugated goat antirabbit IgG (111-036-
045), goat antirat horseradish peroxidase (HRP) IgG (112-035-167),
rabbit antigoat HRP IgG (305-036-003), and goat antimouse HRP
IgG (115-036-003; Jackson ImmunoResearch Laboratories).
Cell Lines and Culture Conditions
B16-F1 mouse melanoma cells were maintained in Eagle’s mini-
mum essential medium (EMEM) supplemented with 10% fetal bovine
serum (FBS), sodium pyruvate, nonessential amino acids, L-glutamine,
a vitamin solution (all from Life Technologies, Grand Island, NY), and
a penicillin/streptomycin mixture (Flow Laboratories, Rockville, MD).
The cells were maintained at 37°C in a mixture of 5% CO2 and 95%
air. The lymphatic endothelial cells [18] and brain microvascular endo-
thelial cells [19] derived from H-2kb-tsA58 mice have been described
previously. Both of these cell lines were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% FBS and the pre-
viously mentioned supplements. All cell lines were determined to be
free of mycoplasma and pathogenic murine viruses (assayed by Science
Applications International Co, Frederick, MD).
Western Blot Analysis
It is well established that endothelial cells from different regional
circulations are structurally and functionally distinct [20,21]. To con-
firm that the lymphatic endothelial cells used in our study main-
tained characteristic feature of lymphatic endothelial cells in vivo and
that these cells could be distinguished from blood vascular endothelial
cells, we compared the expression of VEGFR-3 and Prox1 in mono-
layers of lymphatic endothelial cells and brain microvascular endothe-
lial cells. The brain endothelial cells were derived from the same mouse
line (H-2K b-tsA58 mice) and were selected for comparative analysis
because the brain does not possess lymphatic vessels. We were also
interested in determining expression of the inducible endothelial cell
adhesion molecule, VCAM-1, given that this glycoprotein seems to
play a prominent role in the blood-borne spread of melanoma [14–
17]. Identical passage (passage 5) lymphatic endothelial cells and brain
endothelial cells were seeded onto 10-cm dishes at a density of 4 ×
105 cells per dish in DMEM containing 10% FBS. The cells were
maintained in a 37°C incubator for a period 96 hours, at which time
the medium was aspirated, and the cells were washed twice with PBS
and then lysed with buffer (50 mM Tris-HCl [pH 7.5], 50 mMNaCl,
1% Triton X-100, 1 mM Na3VO4, and protease inhibitors).
Protein concentrations were determined using the Bradford method
(Bio-Rad Laboratories, Hercules, CA). Total protein (50 μg) was re-
solved in 8% SDS–polyacrylamide gel electrophoresis under reducing
conditions and transferred to polyvinylidene disulfide membranes.
Membranes were blocked with 5% (wt./vol.) nonfat dried milk in
0.1% Tween 20 (Sigma) in PBS for 1 hour and incubated overnight
with antibody directed against VEGFR-3 (BD PharMingen; 1:200),
Prox1 (1:1000), or VCAM-1 (Santa Cruz Biotechnology; 1:500). β-Actin
(Sigma-Aldrich)was used as an internal loading control. Immunodetection
was performed using the corresponding secondary HRP-conjugated
antibody, and activity was detected using enhanced chemilumines-
cence (Amersham Biosciences, Piscataway, NJ).
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To evaluate the expression levels of chemokine receptors on the
B16-F1 cell lines, protein lysates from B16-F1, B16α4+, and B16α4−
melanoma cells were separated on SDS–polyacrylamide gel electropho-
resis (10%) under reducing conditions and transferred to polyvinylidene
disulfide membranes for immunoblot analysis with antibodies spe-
cific for CXCR-3 (1:100), CXCR-4 (1:500), CCR-7 (1:3000), and
CCR-10 (1:1000).
Generation of B16-F1 Melanoma Cell Lines Based on
Expression Levels of the α4 Integrin
Monolayers of B16-F1 cells (70-80% confluent) were harvested by
briefly exposing the cells to a solution containing 0.25% trypsin and
0.02% EDTA. The cells were resuspended in EMEM containing 5%
FBS, centrifuged for 10 minutes at 200g, and then prepared for cell
sorting. We incubated 2 × 105 cells with 20 μl of an antibody directed
against the N-terminus of the α4 integrin (BD PharMingen) for 45 min-
utes at 4°C, washed the cells twice with serum-free medium, and then
resuspended them in EMEM containing 5% FBS. Cells were then
incubated with an FITC-conjugated antirat secondary antibody for
45 minutes at 4°C, washed twice, and resuspended in 1 ml of EMEM
containing 5% FBS. Cell staining was evaluated with a Beckman Epics
Elite flow cytometer (Beckman Coulter, Miami, FL) equipped with
an air-cooled argon ion laser. The emission wavelength used for the
recognition of FITC was 520 nm, and gating parameters were adjusted
based on the fluorescence histograms for the negative controls. B16-F1
melanoma cells expressing high (B16α4+) and negligible (B16α4−)
levels of α4 were collected in sterile tubes containing 5% EMEM
and transferred to T-25 flasks. The cells were expanded and subjected
to an enrichment sort using the methodology described previously.
Adhesion of B16-F1 Cell Lines to Lymphatic Endothelial
Cell Monolayers
We studied the ability of B16-F1, B16α4+, and B16α4− cells to
stably adhere to monolayers of lymphatic endothelial cells. Lymphatic
endothelial cells were seeded onto 96-well plates at a density of 3 ×
103 cells per well in DMEM containing 10% FBS and grown to con-
fluence (6 days). Cultures of tumor cells that were 70% to 80% con-
fluent were labeled with Vybrant DiI cell-labeling solution (Molecular
Probes) according to the manufacturer’s instructions. After a 1-hour
incubation period, we confirmed fluorescent labeling of the tumor cells
and then aspirated the medium from the 96-well plates containing
lymphatic endothelial cells. B16-F1, B16α4+, and B16α4− cells were
prepared at a concentration of 2.5 × 104 cells/ml in EMEM containing
5% FBS, and 100 μl of this tumor cell–containing medium was added
into individual wells that contained lymphatic endothelial cells. The
tumor cells were incubated with the lymphatic endothelial cells for
30 minutes at 37°C. After this period, the medium was aspirated,
and the wells were washed twice with EMEM to remove any unbound
tumor cells. The number of adherent tumor cells in each well was
determined by counting the number of fluorescently labeled cells in
each well under magnification (100×) using an Axioplan II fluores-
cence microscope (Carl Zeiss, Inc, Thornwood, NY).
Contribution of α4β1–VCAM-1 to Adhesion of B16-F1
Melanoma Cells to Lymphatic Endothelial Cells and Brain
Microvascular Endothelial Cells
To study the contribution of α4β1–VCAM-1 to tumor cell adhe-
sion, we first blocked any Fc receptor present on both lymphatic
endothelial cells and brain-derived endothelial cells by incubating
each cell type with 1 μg/ml of antimouse CD16/CD32 antibody
(PharMingen) in EMEM containing 5% FBS for 1 hour at 37°C. After
this period, the medium was aspirated and replaced with EMEM con-
taining either 10 or 15 μg/ml of anti–VCAM-1 monoclonal antibody
(PharMingen). The lymphatic endothelial cells and brain endothelial
cells were incubated in the antibody-containing medium for 1 hour.
After this period, the medium from both brain endothelial cells and
lymphatic endothelial cells was aspirated and replaced with medium
containing tumor cells as described previously. In similar experiments,
we incubated B16-F1, B16α4+, and B16α4− melanoma cells with 1 or
5 μg/ml of an anti-α4 antibody for 1 hour before their coincubation
with lymphatic or brain endothelial cells. In both series of studies, the
number of adherent cells was compared with control. In other experi-
ments, both VCAM-1 and α4 integrins were blocked simultaneously
before the addition of tumor cells. For the experimental control in the
VCAM-1 experiments, the lymphatic endothelial cells were incubated
with 15 μg/ml of an isotype control antibody, whereas in the α4 ex-
periments, the B16-F1 cell lines were incubated with 5 μg/ml of an
isotype standard antibody. All of the tumor cell adhesion experiments
were repeated at least four times.
Animals and B16-F1 Tumor Models
C57BL/6J mice and athymic nude mice (NCI-nu) were purchased
from the Animal Production Area of the National Cancer Institute
Frederick Cancer Research and Development Center (Frederick, MD).
The mice were housed and maintained under specific pathogen-free
conditions in facilities approved by the American Association for Ac-
creditation of Laboratory Animal Care and in accordance with current
regulations and standards of the US Department of Agriculture, the US
Department of Health and Human Services, and the National Insti-
tutes of Health. The mice were used, in accordance with institutional
guidelines, when they were 6 to 8 weeks old.
To produce melanoma tumors, we harvested B16-F1, B16α4+, and
B16α4− melanoma cells from subconfluent cultures by briefly expos-
ing the cells to a solution containing 0.25% trypsin and 0.02% EDTA.
The cells were washed twice and then resuspended in Hanks’ buffered
saline solution. The cell concentration was adjusted to ensure that a
volume of 100 μl was delivered into the subcutaneous space of each
mouse. Melanoma cell injection into the pinna was performed as pre-
viously described [22]. For surgical resection of primary melanoma tu-
mors, mice were anesthetized with an intraperitoneal injection of
pentobarbital sodium (Abbott Laboratories, North Chicago, IL). Mice
were prepared with a betadine solution, and hemostasis was controlled
using a portable electrocautery device (Braintree Scientific, Braintree,
MA). Stainless steel wound clips were used for surgical closure.
Necropsy Procedures and Histologic Studies
Mice were killed with pentobarbital sodium, and their body weights
were recorded. After necropsy, tumors were excised, and the tumor
weight was recorded. For immunohistochemical and hematoxylin and
eosin staining procedures, a portion of the tumor was fixed in formalin
and then embedded in paraffin. Another portion of the tumor was em-
bedded in ornithine carbamyl transferase compound (Miles Laborato-
ries, Elkhart, IN), rapidly frozen in liquid nitrogen, and stored at −80°C.
All of the ipsilateral axillary lymph nodes, inguinal lymph nodes, and
lungs were harvested and processed in a similar fashion. The presence
of metastatic disease was determined by histologic examination.
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Immunofluorescent Staining of B16-F1 Tumors for Lymphatic
Vessels (LYVE-1), VCAM-1, and α4 Integrin
We used frozen tissues to identify lymphatic vessels, VCAM-1,
and the α4 integrin. Frozen sections of B16-F1 tumors that were har-
vested from C57BL/6J mice were mounted on slides and fixed using
a protocol consisting of three sequential immersions in ice-cold so-
lutions containing acetone, 50:50 (vol./vol.) acetone-chloroform, and
acetone (5 minutes each). Samples were incubated in a blocking solu-
tion containing 5% normal horse serum and 1% normal goat serum
in PBS for 20 minutes at room temperature and were then incubated
with antibody directed against LYVE-1, VCAM-1, or α4 integrin
(each antibody used at 1:100 dilution) at 4°C overnight. The samples
were washed three times in PBS, incubated with a blocking solution,
and then incubated for 1 hour with either a 1:1500 dilution of Alexa
488 antibody (for LYVE-1) or a 1:1200 dilution of Alexa 594 anti-
body (for VCAM-1 and α4). Control samples were incubated with
goat antirabbit IgG and goat antirat IgG isotype primary antibodies
and with Alexa 488 and Alexa 594 fluorescent secondary antibodies.
All samples were rinsed and incubated with Hoechst stain (Poly-
sciences, Inc, Warrington, PA) to visualize the cell nuclei. The slides
were mounted with a glycerol/PBS solution containing 0.1 M propyl
gallate to minimize fluorescent bleaching. Immunofluorescent micros-
copy was performed using a Zeiss Axiplan fluorescent microscope
(Carl Zeiss, Inc) equipped with a 100-W Hg lamp and narrow band-
pass excitation filters. Images were obtained using a cooled charge-
coupled device Hamamatsu C5810 camera (Hamamatsu Photonics,
Bridgewater, NJ) and ImagePro software (Media Cybernetics, Silver
Spring, MD). Composite images were created using Photoshop soft-
ware (Adobe Systems, Inc, Mountain View, CA).
Determination of Lymphatic Vascular Density
Lymphatic vascular density (LVD) in the B16-F1 and B16α4+ tu-
mors was determined as previously described [23]. In brief, tumors
were examined microscopically to identify regions that stained intensely
for LYVE-1 by low-power (original magnification, ×40) scanning of
the section. The mean LVD was quantified by counting the number
of lymphatic vessels at high magnification (original magnification,
×100) in a minimum of five microscopic fields for each tumor sample.
Tumor Cell Proliferation In Vitro
B16 melanoma cell lines were plated into 96-well plates in 100 μl
of EMEM containing 5% FBS at a density of 7.0 × 103 cells per well.
After a 24-hour incubation at 37°C, the medium was aspirated and
replaced with 200 μl of EMEM containing 5% FBS, and the plates
were placed in a 37°C incubator. After 72 hours, metabolically active
cells were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenol-
tetrazolium bromide (MTT) assay [24]. MTT conversion to formazan
by metabolically active cells was measured at 570 nm using an MR-
5000 96-well microtiter plate reader (Dynatech, Inc, Chantilly, VA).
Statistics Analysis
Statistical analyses were performed using GraphPad Prism software
(San Diego, CA). P values for adhesion assays and MTT assays were
calculated using one-way analysis of variance. Means determined to be
significantly different (P < .05) were then subjected to post hoc analysis
using Tukey’s multiple comparison testing. The sizes of primary mel-
anoma tumors were compared using Student’s t test. Comparison be-
tween the incidences of lymph node metastases was determined using
Fisher’s exact probability testing.
Results
In Vitro Expression of VEGFR-3, Prox1, and VCAM-1 in
Lymphatic Endothelial Cells
Western blot analysis was performed to determine expression of
VEGFR-3, Prox1, and VCAM-1 in cultures of lymphatic endothelial
cells and identical passage brain microvascular endothelial cells.
VEGFR-3 and Prox1 are considered markers of lymphatic endothelia
in vivo but not of most blood vascular endothelial cells [25]. Lym-
phatic endothelial cells expressed marked amounts of VEGFR-3 and
Prox1, whereas expression of these two proteins in brain microvas-
cular endothelial cells was markedly reduced (Figure 1). We also mea-
sured expression of VCAM-1 in each of the endothelial cell lines
because this protein has been implicated in the hematogenous spread
of melanoma. We noted that expression of VCAM-1 was significantly
more pronounced in lymphatic endothelial cells when compared with
that in brain endothelial cells (Figure 1).
Expression of α4 Integrin in B16-F1, B16α4−, and B16α4+
Melanoma Cells
Consistent with reports from other laboratories [26], we noted that
B16-F1 murine melanoma cells express elevated levels of the α4 in-
tegrin in vitro (Figure 2, A and B). However, we were able to identify
and isolate a subpopulation of cells that did not express measurable
levels of α4 and designated these cells B16α4−. We also isolated a pop-
ulation of cells that expressed very high levels of the α4 integrin on
their surface and termed these cells B16α4+. Measurements of the
amount of α4 integrin expressed by B16α4+ cells indicated that ex-
pression on these cells was three-fold higher than expression on the
B16-F1 cell line. B16α4+ and B16α4− cell lines were expanded and
subjected to an enrichment sort.
An examination of the B16-F1, B16α4−, and B16α4+ cell lines
growing in cell culture conditions revealed marked differences with re-
spect to cell morphology. For example, the B16α4− cells have a more
rounded morphology and tend to grow as single entities, whereas the
B16 melanoma cells that are enriched in α4 (B16α4+) were much
more likely to form homotypic cell interactions (Figure 2B). Both of
these growth patterns could be observed in cultures of the parental
Figure 1. Expression of VEGFR-3, Prox1, and VCAM-1 by lymphatic
endothelial cells and brain-derived microvascular endothelial cells.
Immunoblot analysis results show that lymphatic endothelial cells
retain their characteristic features despite transfer to cell culture.
Lymphatic endothelial cells (LyEC) express high levels of VEGFR-3,
Prox1, and VCAM-1 compared with brain-derived vascular endothe-
lial cells (BrEC). β-Actin is shown as an internal loading control.
176 Integrins and Melanoma Metastasis Rebhun et al. Neoplasia Vol. 12, No. 2, 2010
B16-F1 melanoma cell line. The expression levels of α4 integrins and
individual growth patterns observed in the different B16 melanoma
cell lines remained stable for a period of at least 6 weeks in cell culture
(data not shown). The turnover time of B16α4+ cells growing in cell
culture was slightly longer than that of B16-F1 and B16α4− tumor
cells (Figure 3A). However, the adhesion of B16α4+ cells to lymphatic
endothelial cells was significantly greater than the B16-F1 melanoma
cells and the α4-deficient B16α4− melanoma cells (Figure 3B).
B16-F1 Melanoma Cell Adhesion to Lymphatic Endothelial
Cells, but not Brain Microvascular Endothelial Cells,
Is Mediated by VCAM-1
To more directly examine the contribution of the melanoma cell
α4 integrin to lymphatic endothelial cell adhesion, we performed a
series of antibody-blocking experiments with B16-F1 melanoma
cells. We also compared B16-F1 tumor cell adhesion to brain micro-
vascular endothelial cells to determine whether the tumor cells used a
common receptor to adhere to endothelial cells from different tissues.
Tumor cell adhesion to lymphatic endothelial cells was significantly
attenuated by blocking VCAM-1 on lymphatic endothelial cells (Fig-
ure 4A) and also by blocking the α4 integrin on melanoma cells (Fig-
ure 4B). Simultaneous blockade of both VCAM-1 on endothelial
cells and α4 integrins on melanoma cells did not result in any ad-
ditional reduction in tumor cell adhesion. This antibody-blocking
strategy had no effect on B16-F1 melanoma cell adhesion to brain
endothelial cells (Figure 4, A and B). The results of these experiments
suggest that the ability of melanoma cells to stably adhere to lym-
phatic endothelial cells is largely dependent on α4β1–VCAM-1 inter-
actions. The results also indicate that melanoma cells may rely on
different receptor-ligand pairs to facilitate their adhesion to vascular
endothelium of different tissues.
Tumorigenicity and Lymph Node Metastasis of B16-F1
Melanoma Cells Expressing Different Levels of α4 Integrin
To determine whether the differential expression of α4 integrin in
the B16 melanoma cell lines had any effect on tumor growth and
Figure 2. Expression of α4 by B16 melanoma cell lines. (A) Selection of variant sublines from the parental B16-F1 melanoma cells was
performed as described within the text. Successive selection from the B16-F1 cells yielded a subline that expressed high levels of α4
(B16α4+) and a subline that was deficient in α4 integrin (B16α4−). (B) Immunohistochemical staining of α4 and representative examples
of morphologic differences as observed with phase-contrast microscopy. When compared with B16-F1 melanoma cells, B16α4− cells
display decreased homotypic adhesion in vitro, whereas B16α4+ cells are more inclined to form cell-cell aggregates.
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metastasis in mice, we injected B16-F1, B16α4−, and B16α4+ tumor
cells into the subcutaneous space of C57BL/6J mice. Whereas injec-
tion of B16-F1 and B16α4+ into mice resulted in a 100% tumor
take within 3 weeks of injection, B16α4− cells were unable to gener-
ate a tumor even after 8 weeks after tumor cell injection. On the basis
of these results, additional experiments were performed to determine
the minimal number of tumor cells required to produce a tumor. We
found that subcutaneous injection of 5 × 103 cells was the minimum
number of B16-F1 and B16α4+ tumor cells needed for tumor for-
mation. In contrast, even as many as 4 × 105 tumor cells from the
B16α4− cell line were insufficient to produce a tumor (data not shown).
B16α4− tumor cells were also unable to form tumors in athymic nude
mice, suggesting that the lack of tumor formation was not due to
immune rejection. These data suggest that melanoma cell expression
of α4 integrins may be a prerequisite for tumorigenesis.
Experiments were performed to determine the correlation between
expression of the α4 integrin and regional lymph node metastasis.
Mice were injected with B16-F1 or B16α4+ melanoma cells (5 ×
104 cells) into the mouse flank, and 21 days later, the primary tumors
were surgically resected, and the wounds closed with stainless steel
wound clips. All mice were killed 3 weeks later, and the lymph nodes
were harvested for histologic evaluation. We found that 30% of mice
with B16-F1 tumors developed lymph node metastases, whereas
80% of mice with B16α4+ tumors formed lymph node metastases
(Table 1). The frequency of pulmonary metastases in B16-F1 and
B16α4+ tumors was low (10% and 20%, respectively), and there
were no significant differences between the two groups. Whereas
the rate of cell division of B16α4+ tumor cells growing in cell culture
was significantly slower than B16-F1 and B16α4− tumor cells (Fig-
ure 3A), B16α4+ tumors growing in mice were significantly larger
than B16-F1 tumors.
Expression of Chemokine Receptors on B16-F1, B16α4−, and
B16α4+ Melanoma Cells
Recent studies have shown that chemokines and their receptors
play an important role in melanoma tumorigenesis and metastasis
[27], so we next examined expression levels of four chemokine recep-
tors that have been associated with melanoma progression. Each of
the B16 cell lines expressed similar amounts of CXCR-4, CCR-7,
and CCR-10 as determined by Western blot analysis, whereas expres-
sion of CXCR-3 was slightly decreased on B16α4− tumor cells when
compared with either parental or B16α4+ cells (Figure 5). The pat-
terns of chemokine receptors expressed by the different B16 melanoma
cells do not satisfactorily explain the enhanced metastatic potential
of the B16α4+ melanoma cells or explain the diminished capacity of
the B16α4− cells to form tumors.
Figure 3. Analysis of B16 melanoma cell proliferation and mela-
noma cell adhesion to lymphatic endothelial cells. (A) Cell prolifer-
ation of B16-F1 melanoma cell lines in vitro was assessed by MTT.
Cell division of both B16-F1 and B16α4− tumor cells was signifi-
cantly greater than the growth of B16α4+ melanoma cells. (B) The
adhesion of B16α4+ to lymphatic endothelial cells is seven times
greater than the adhesion of B16α4−melanoma cells. Data are ex-
pressed as mean ± SEM and repeated at least four times with
comparable results.
Figure 4. B16-F1 melanoma cell adhesion to lymphatic endothelial
cells and brain microvascular endothelial cells. (A) Blockade of
VCAM-1 expressed on lymphatic endothelial cells results in a sig-
nificant reduction in number of adherent tumors cells to lymphatic
endothelial cells, whereas the same treatment has no effect on
tumor cell adhesion to brain endothelial cells. (B) Blockade of the
melanoma cell α4 integrin also results in dose-dependent reduction
in tumor cell adhesion to lymphatic endothelial cells. Identical treat-
ment has no effect on ability of melanoma cells to adhere to brain
endothelial cells. Data are expressed as mean ± SEM. *P < .05,
**P < .001.
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Lymphatic Vascular Density and Expression of LYVE-1, α4
Integrin, and VCAM-1 in B16-F1 and B16α4+ Tumors
To determine whether the increase in lymphatic metastasis ob-
served in B16α4+ tumors was the result of an increase in LVD, we
quantified the number of lymphatic vessels associated with B16-F1
tumors and B16α4+ tumors. We observed lymphatic vessels in the
peritumoral region of both tumors (Figure 6B). However, there were
no significant differences between the mean number of lymphatic
vessels in B16-F1 and B16α4+ tumors (data not shown). Hence,
the increase in lymph node metastasis observed in B16α4+ tumors
was not the result of an increase in lymphatic vascular surface area.
We then used immunofluorescent staining to evaluate expression
of VCAM-1 and the α4 integrin in the B16 melanoma tumors.
VCAM-1 was present in both B16-F1 and B16α4+ tumors (Fig-
ure 6C ), and moreover, the glycoprotein was localized to lymphatic
vessels (Figure 6D). Similarly, the pattern of α4 integrin expression
that we observed in vitro was conserved in vivo. That is, B16-F1
parental tumors expressed the α4 integrin (Figure 6E ), but the ex-
pression was considerably more pronounced in B16α4+ tumors (Fig-
ure 6F ). In the B16α4+ tumors, we could also observe tumor cells
interacting with the peritumoral lymphatic vessels, and in several in-
stances, the tumor cells had gained access to the lymphatic vessels
(Figure 6, G and H ).
Discussion
Lymphatic vessels facilitate the spread of melanoma cells to regional
lymph nodes and distal tissues, and melanoma patients are required
to undergo a comprehensive clinical inspection of the lymphatic
compartment to determine tumor stage, prognosis, and appropriate
therapeutic intervention. However, there is a paucity of data regard-
ing the cellular and molecular interactions that take place between
melanoma cells and lymphatic endothelial cells. In the present report,
we examined how expression of α4 integrins on melanoma cells af-
fects their ability to interact with lymphatic endothelial cells in vitro
and how it impacts metastasis to regional lymph nodes in vivo. The
results of these studies provide new insight into lymphatic metastasis
including the following: 1) melanoma cell adhesion to lymphatic en-
dothelial cells is mediated by the α4 integrin receptor on melanoma
cells binding to its counterreceptor, VCAM-1, which is constitutively
expressed on lymphatic endothelial cells; 2) VCAM-1 is expressed on
melanoma-associated lymphatic vessels in vivo; 3) there is a direct
correlation between levels of α4 integrin expression on melanoma
cells and lymphatic metastasis; and 4) melanoma cell adhesion to
brain endothelial cells occurs through a VCAM-1–independent pro-
cess. During our investigation, we also determined that melanoma
tumorigenesis is also dependent on the α4 integrin.
The adhesive interactions that take place between tumor cells and
endothelial cells of the blood vasculature are widely regarded as a key,
rate-limiting step in hematogenous metastasis [28]. To date, however,
it remains unclear whether tumor cells exploit endothelial cell adhe-
sion molecules to form stable adhesive interactions with lymphatic
vessels. Recent results from investigations of leukocyte trafficking
would argue that cell navigation through lymphatic channels is not
so dissimilar from the cell migration that occurs in the blood vascu-
lar system and that endothelial cell adhesion molecules, including
VCAM-1, play a critical role in this process [29,30]. Nevertheless, pre-
vious reports have emphasized that the size of the primary melanoma
is the principal factor that determines whether tumor cells will me-
tastasize to regional lymph nodes. For example, Nathanson et al. [31]
reported that there was a direct correlation between the size of B16
melanoma tumors and the occurrence of both lymphatic and pul-
monary metastasis. In our study, we did not observe any correlation
between pulmonary metastasis and tumor size. We did, however, ob-
serve a correlation between tumor size and metastasis to lymph
nodes. In addition to the size of the primary tumor, we propose a
Table 1. Tumor Size and Incidence of Spontaneous Lymph Node and Lung Metastasis.
Melanoma Cell Line Primary Tumor Incidence Tumor Volume* (mm3) Lymph Node Metastases Lung Metastases
B16-F1 10/10 877† (463-1183) 3/10‡ 1/10
B16α4+ 10/10 1852
† (958-2912) 8/10‡ 2/10
B16α4− 0/10† — — —
B16 melanoma cell lines (5 × 104/100 μl) were injected subcutaneously into the flank of C57BL/6J mice. Three weeks later, tumors were surgically resected and mice were allowed to recover. Two weeks
after resection, mice were euthanized and evidence of metastasis was determined histologically.
*Tumor volume was given as mean (range).
†P ≤ .01.
‡P ≤ .05.
Figure 5. Chemokine receptor expressionbyB16melanomacell lines.
Immunoblot analysis results demonstrate that B16-F1, B16α4+, and
B16α4− express similar amounts of the chemokine receptors CCR-
10, CCR-7, and CXCR-4. CXCR-3 expression was slightly greater in
B16-F1 cells in comparison to B16α4+ and B16α4− melanoma cells.
β-Actin is shown as an internal loading control.
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mechanism for melanoma lymph node metastasis that is related to the
ability of tumor cells to adhere to the lymphatic vasculature. We base
this assertion on our data that show a direct correlation between the
ability of B16-F1 melanoma cells to adhere to lymphatic endothelial
cells and the ability of these cells to generate lymphatic metastases.
VCAM-1 is a cytokine-inducible endothelial cell adhesion mole-
cule that belongs to the immunoglobulin superfamily of receptors
[32]. During an inflammatory response, VCAM-1 becomes upregu-
lated on the surface of vascular endothelial cells, where it mediates the
firm adhesion and transmigration of blood leukocytes [32]. Aberrant
Figure 6. VCAM-1 is expressed on B16 tumor-associated lymphatic endothelial cells. (A–D) Double immunostaining for the lymphatic
specific marker LYVE-1 (green) and VCAM-1 (red) reveals colocalization (yellow) of VCAM-1 and LYVE-1 on B16 tumor-associated lym-
phatic vessels. Nuclei are stained with Hoescht (blue). (E) The intensity of α4 integrin expression (red) in parental B16-F1 tumors is
significantly reduced in comparison to expression found in (F) B16α4+ tumors. (G, H) LYVE-1 (green) and α4 (red) expressions at the
peritumoral region of B16α4+ tumors growing subcutaneously. B16α4+ tumor cells (confirmed with hematoxylin and eosin staining) can
readily be identified around and within peritumoral lymphatic vessels.
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expression of VCAM-1 has been implicated in the initiation and
perpetuation of several pathological disorders such as atherosclerosis
[33], colitis [34], and arthritis [35]. Studies performed on human um-
bilical vein endothelial cells that were stimulated with proinflamma-
tory cytokines were the first to show that VCAM-1 could support
the adhesion of melanoma cells [36]. Experimental models of mela-
noma metastasis provided support for the in vitro data in that anti-
bodies directed against VCAM-1 or the α4 integrin significantly
attenuated the number of pulmonary metastases in mice that had
been pretreated with inflammatory cytokines [16]. The results of
the present report are unique in that we found that the constitutive
expression of VCAM-1 by lymphatic endothelial cells is sufficient to
support melanoma cell adhesion. We also noted that the lymphatic
vessels associated with B16 melanomas growing in mice express con-
stitutive levels of VCAM-1. Whereas the in vivo data lend some cred-
ibility to the lymphatic endothelial cells used in our study, the results
also add to the growing evidence that suggests VCAM-1 is an im-
portant cofactor in the tissue-specific spread of melanoma. Gene ex-
pression profiles comparing endothelial cells derived from lymphatic
vessels and from blood vessels suggest that each cell type possesses
a distinct molecular signature [37]. Studies of two circulations in
the whole animal have determined that one of the key features that
distinguish lymphatic endothelium from blood vascular endothelium
is that lymphatic endothelial cells constitutively express the transcrip-
tion factor nuclear factor κB (NF-κB) [38]. NF-κB has been shown
to be a central regulator of VCAM-1 expression [39] and, hence,
may be responsible for the constitutive expression of VCAM-1 ob-
served in the lymphatic vessels of melanoma tumors. Collectively,
these data may help to explain the proclivity of melanoma to spread
through the lymphatic system. Studies are ongoing to compare
VCAM-1 expression levels in nonpathologic tissues with expression
in other tumor models.
The results of our studies demonstrate that, as the level of α4 integ-
rin expressed on melanoma cells increases, there is a greater likelihood
that these cells will spread to regional lymph nodes. Our findings are
in stark contrast to a previously published report that found that ex-
pression of α4β1 on melanoma cells inhibits the invasive stage of
metastasis formation [40]. The authors of that article reported that
melanoma cells that express α4β1 integrins have a greater tendency
to form homotypic cell-cell aggregates and, therefore, cannot assume
the phenotype necessary for invasion. We also observed that the
B16α4+ cells that overexpressed the α4 integrin had a greater tendency
to form homotypic interactions in cell culture; however, this pattern of
growth did not preclude tumor cells from invading adjacent lymphatic
vessels and metastasizing to regional lymph nodes. The discrepancy in
the results of the two studies may be related to fundamental differences
in experimental design in that we directed our attention to lymphatic
spread, whereas the previous report focused on lung metastases. In sev-
eral tumor sections taken from B16α4+ tumors, we noted α4-positive
tumor cells in contact with the wall of LYVE-1–positive lymphatic ves-
sels and, in some instances, inside the lymphatic vessel lumen. The
results of the present work are consistent with clinical data demonstrat-
ing that α4 is absent in benign nevi and becomes increasingly ex-
pressed during tumor progression.
Investigations of the mechanisms that regulate the patterns of
metastasis of malignant tumors have determined that tissue-specific
gradients of chemoattractant cytokines, called chemokines, play an im-
portant role in the recruitment of tumor cells to distinct anatomic sites
[41]. One of the primary biologic functions of the chemokine proteins
is to provide the directional information necessary for leukocyte traf-
ficking processes [42]. For example, the chemokine CCL21 is consti-
tutively expressed in secondary lymphoid organs and is responsible
for the homing of CCR-7 expressing lymphocytes and dendritic cells
to lymph nodes [43]. We were interested in determining the expres-
sion of chemokine receptors on our cells because some chemokines,
such as CXCL12, have been shown to enhance the affinity of α4 in-
tegrins for VCAM-1 [44]. In addition, recent studies have shown that
melanoma cells that overexpress CCR-7 are much more likely to
metastasize to lymph nodes than melanoma cells that are deficient
in the receptor [45]. However, we found no differences in the amount
of CCR-7 expressed on the different B16 cell lines, and hence, we
concluded that the expression of this receptor alone does not account
for the differences that we observed in the metastatic potential. The
chemokine receptors CXCR-3 and CXCR-4 have also been implicated
in lymphatic metastasis [46,47], but their expression did not correlate
with lymphatic metastasis in our study. In all likelihood, the dissemi-
nation of tumor cells to lymph nodes is more complex than previously
considered and may require successful completion of a coordinated
series of interactions similar to those that take place during hematog-
enous metastasis.
Whereas the primary objective of our study was to examine mel-
anoma cell interactions with lymphatic endothelial cells, our results
also demonstrated that the α4 integrin may be essential for tumori-
genesis of B16 cells. Although B16-F1 and B16α4− cells grew more
rapidly in culture than B16α4+ cells, the α4-deficient B16α4− cells
were unable to form tumors in syngeneic C57BL mice. The B16α4−
cells were also unable to establish tumors in athymic nudemice, suggest-
ing that the lack of tumorigenicity was not related to enhanced immune
clearance of the B16α4− cells. Studies of integrin expression on neural
crest cells, the population of cells from which melanoma cells are de-
rived, have determined that α4β1 plays an essential role in cell survival
by protecting these cells from programmed cell death [48]. Other stud-
ies have reported that the expression of α4β1 promotes the survival of
retinal ganglion cells [49] and CD34+ bone marrow progenitor cells
[50]. Whether the α4-deficient B16α4− cells are unable to divide when
implanted into the animal and/or activate programs that regulate their
destruction requires further investigation. Nevertheless, identifying the
molecular phenotype of themelanoma cell population with tumorigenic
potential is critical for the development of novel anticancer therapies.
Our data suggest that melanoma cells with both tumorigenic and meta-
static properties express the α4 integrin.
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